Abstract: A load switch includes a switch input, a switch output, a first field-effect transistor (FET), and a second FET. The switch input is adapted to be coupled to a controller output of a controller. The switch output is adapted to be coupled to a controller input of the controller. The first FET has a gate and a source. The gate of the first FET is coupled to the switch input. The second FET has a gate and a source. The gate of the second FET is coupled to the source of the first FET. The source of the second FET is coupled to the switch output.

Abstract: The disclosure provides a eutectic ceramic thermal barrier material and a preparation method thereof, which relates to the field of composite materials. The present disclosure provides a eutectic ceramic thermal barrier material comprising a nickel-based superalloy substrate, an intermediate binding layer and a eutectic ceramic cladding layer stacked sequentially; the intermediate binding layer comprises a NiCoCrAlY binding layer; the eutectic ceramic cladding layer comprises an Al2O3/GdAlO3 binary eutectic ceramic coating or an Al2O3/GdAlO3/ZrO2 ternary eutectic ceramic coating. The eutectic ceramic thermal barrier material provided by the present disclosure has good high temperature resistance, good oxidation resistance and excellent mechanical properties.

Abstract: A driving method, a driving circuit and a touch-display apparatus are provided. The driving method includes providing a gate driving signal to a gate line, providing a pixel voltage to a data line, and providing a common electrode driving signal to a common electrode, wherein a pixel display operation is performed based on the gate driving signal, the pixel voltage, and the common electrode driving signal, and simultaneously, a touch detection operation is performed based on the common electrode driving signal. The driving method realizes the effect of simultaneously performing a pixel display operation and a touch detection operation, and solves the problem that the pixel display operation of the touch-display apparatus is affected in the touch detection stage.

Abstract: A display panel, a display device and a driving method. The display panel includes a display region and a peripheral region. The display region includes a subpixel unit array having a plurality of rows and a plurality of columns of subpixel units, and the peripheral region includes a gate drive circuit. The display region further includes a plurality of gate lines and a plurality of data lines. Each subpixel unit is driven by a scanning signal provided by one gate and a data signal provided by one data line, and a same data line is connected with at least two subpixel units which are not adjacent to each other and have a same color. The gate drive circuit includes a plurality of shift register units, and the plurality of gate lines are electrically connected with the plurality of shift register units in a one-to-one correspondence in order.

Abstract: A load switch includes a switch input, a switch output, a first field-effect transistor (FET), and a second FET. The switch input is adapted to be coupled to a controller output of a controller. The switch output is adapted to be coupled to a controller input of the controller. The first FET has a gate and a source. The gate of the first FET is coupled to the switch input. The second FET has a gate and a source. The gate of the second FET is coupled to the source of the first FET. The source of the second FET is coupled to the switch output.

Abstract: A driving circuit includes at least one first module, an electrostatic charge/discharge module connected to the first module and a grounding module; each first module includes a driving module, a signal transmission module and a gating module; the signal transmission module is connected to and transmits a driving signal to the driving module; the grounding module is grounded; the gating module is connected with the signal transmission module; the gating module is turned on with its turn-on voltage less than or equal to a voltage of the signal transmission module, or turned off with the turn-on voltage greater than the voltage of the signal transmission module; the turn-on voltage of the gating module is greater than that of the driving module; the charge/discharge module is connected to the gating module and the grounding module, and configured to store charges flowing therethrough and release the charges to the grounding module.

Abstract: A device and a method for continuous temperature gradient heat treatment of a rod-shaped material are disclosed. The furnace body of the device includes an upper heating zone and a lower heating zone inside, which are independently controlled in temperature by means of an upper heating power supply and a lower heating power supply. Moreover, both the upper heating zone and the lower heating zone are closed heating zones. The closed heat insulation plates could prevent heat loss and ensure precise temperature control of the upper heating zone and the lower heating zone. In the device, a vacuum pumping equipment is included; an annular radiation screen is configured between the upper heating zone and the lower heating zone, and the rod-shaped material is not in contact with the annular radiation screen. The rod-shaped material conducts one-dimensional heat transfer along the axial direction.

Abstract: In the method for preparing single crystal superalloy test bars by using a Ni—W heterogeneous seed crystal, on the premise of ensuring that the single crystal superalloy has the required orientation, by reusing the seed crystal, it is achieved that the trouble caused by the need of preparing a new seed crystal when a single crystal superalloy is produced by the seed crystal method every time is avoided, and the production cost is significantly reduced. In the present disclosure, the formation of the stray grains in mushy zone could be avoided by using a Ni—W heterogeneous seed crystal without mushy zone and a built-in corundum tube.

Abstract: The present invention relates to a Beclin 1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin 1 coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds.

Abstract: The present invention relates to a Beclin 1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin 1 coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds.

Abstract: The present invention relates to a Beclin1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds.

Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.

Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.

Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.

Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.

Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.

Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.

Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.

Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.

Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.